BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:177Lu-BetaBart readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of 177Lu-BetaBart\, from ClinicalTrials.gov 
 estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07189871-2293@assetmemo.bio
DTSTAMP:20261121T005941Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:177Lu-BetaBart: Phase 1/2 readout est. (NCT07189871)
DESCRIPTION:177Lu-BetaBart\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy
 : 177Lu-BetaBart in Patients With Relapsed/Refractory\, Locally Advanced I
 noperable\, or Metastatic Solid Tumors\nEstimated primary completion: Dece
 mber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/177lu-beta
 bart#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07189871
URL:https://assetmemo.bio/drug/177lu-betabart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
